Immedica Pharma becomes market authorisation holder for Ammonaps® and Ravicti® in Europe


Immedica Pharma AB announced today that Immedica became the Market Authorisation Holder (MAH) for Ammonaps® (Sodium phenylbutyrate) and Ravicti® (Glycerol phenylbutyrate), in 28 EU member countries, Norway and Iceland on 6 June 2019. Ammonaps® and Ravicti®, indicated for the treatment of Urea Cycle Disorders (UCD). In December 2018, Immedica acquired the rights for the products […]